Why the study?
Do genetic polymorphisms (CYP2C19) influence platelet reactivity and ischemic events in patients with acute ischemic stroke treated with clopidogrel?
Population
345 patients hospitalized in Changhai Hospital (China) with acute ischemic stroke
Design
Cohort, randomly enrolled
Follow-up
1 year
Authors
Loading...
High on-clopidogrel reactivity signals ischemic risk in stroke; supports reactivity testing but leaves CYP2C19 genotyping utility open.
Do genetic polymorphisms (CYP2C19) influence platelet reactivity and ischemic events in patients with acute ischemic stroke treated with clopidogrel?
High on-clopidogrel platelet reactivity, influenced by CYP2C19*2 and *3 alleles, is an independent risk factor for ischemic events in acute ischemic stroke patients.
Han et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: